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Abstract
Thyroid peroxidase (TPO) catalyses the biosynthesis of thyroid hormones and is a major auto-
antigen in Hashimoto’s disease—the most common organ-specific autoimmune disease. Epi-
tope mapping studies have shown that the autoimmune response to TPO is directedmainly at
two surface regions on themolecule: immunodominant regions A and B (IDR-A, and IDR-B).
TPO has been amajor target for structural studies for over 20 years; however, to date, the
structure of TPO remains to be determined. We have used a molecular modelling approach to
investigate plausible modes of TPO structure and dimer organisation. Sequence features of
the C-terminus are consistent with a coiled-coil dimerization motif that most likely anchors the
TPO dimer in the apical membrane of thyroid follicular cells. Two contrasting models of TPO
were produced, differing in the orientation and exposure of their active sites relative to the
membrane. Both models are equally plausible based upon the known enzymatic function of
TPO. The “trans”model places IDR-B on the membrane-facing side of themyeloperoxidase
(MPO)-like domain, potentially hindering access of autoantibodies, necessitating considerable
conformational change, and perhaps even dissociation of the dimer into monomers. IDR-A
spans MPO- and CCP-like domains and is relatively fragmented compared to IDR-B, there-
fore most likely requiring domain rearrangements in order to coalesce into one compact epi-
tope. Less epitope fragmentation and higher solvent accessibility of the “cis”model favours it
slightly over the “trans”model. Here, IDR-B clusters towards the surface of the MPO-like
domain facing the thyroid follicular lumen preventing steric hindrance of autoantibodies. How-
ever, conformational rearrangements may still be necessary to allow full engagement with
autoantibodies, with IDR-B on both models being close to the dimer interface. Taken together,
the modelling highlights the need to consider the oligomeric state of TPO, its conformational
properties, and its proximity to the membrane, when interpreting epitope-mapping data.
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Introduction
Thyroid peroxidase (TPO) plays an essential role in thyroid hormone synthesis, catalysing the
iodination of tyrosines on thyroglobulin as well as the synthesis of triiodothyronine and thy-
roxine [1]. TPO is a major autoantigen in autoimmune thyroid diseases (AITDs), encompass-
ing Hashimoto’s thyroiditis and Graves’ disease. Many AITD patients test positive for
autoantibodies against thyroid proteins, in particular TPO (reviewed in [2]). There is evidence
that antibodies against TPO are responsible for the autoimmune destruction of thyrocytes [3],
either by fixing complement or through cell mediated cytotoxicity [4]. However, antibodies
against other thyroid proteins, notably thyroid stimulating hormone receptor (TSHR), may be
more important in some AITDs [5], and antibody-mediated cytotoxicity may be a secondary
mechanism to thyroid destruction [3, 6]. It has also been shown that the complement pathway
may be directly activated by component C4 binding to TPO itself [7].
TPO is a 933-residue transmembrane homodimer [8–10]. It is a largely extracellular protein
that is likely anchored to the apical membrane of thyroid follicle cells by a putative transmem-
brane region at its C-terminal end (residues 847–871) [11, 12]. The N-terminal propeptide
sequence (residues 1–108) is cleaved in the mature protein [13, 14]. Three regions in the TPO
ectodomain (residues 109–846) exhibit a high degree of sequence similarity to domains of
known three-dimensional structure: myeloperoxidase (MPO)-like domain (residues 142–738),
complement control protein (CCP)-like domain (residues 740–795), and epidermal growth
factor (EGF)-like domain (residues 796–846) [15] (Fig 1).
The closest known homologues of TPO are lactoperoxidase (LPO), myeloperoxidase
(MPO), and eosinophil peroxidase (EPO), sharing 48%, 47% and 47% sequence identity with
TPO’s MPO-like domain, respectively. X-ray crystal structures have been determined for MPO
and LPO [16, 17]. Although low-resolution crystals of TPO were reported over 15 years ago
[18, 19], its structure remains to be determined.
Over the last 20 years there have been considerable efforts in mapping the regions of TPO
that are responsible for its autoantigenicity (see [4] and [20] for a review). Epitope mapping
studies with patient autoantibodies, murine monoclonal antibodies and recombinant human
anti-TPO antigen-binding (Fab) fragments reveal that the autoimmune response to TPO is
directed mainly at two surface regions on the molecule: immunodominant region A (IDR-A)
and immunodominant region B (IDR-B) [21–24]. The majority of residues that compose these
two epitopes are found on the MPO-like domain, but there is evidence to suggest that residues
from the neighboring CCP-like domain are also involved [24, 25]. The structural interpretation
of these data is limited by the absence of an experimentally determined structure, so the struc-
tural basis of TPO autoimmunity remains poorly understood.
The X-ray crystal structure determination of human myeloperoxidase (MPO) in 1995 [26]
provided a platform for investigating the structural basis of TPO autoantigenicity, due to the
high sequence similarity between MPO and the MPO-like domain in TPO. The structure of
MPO was used to design and interpret mutagenesis experiments aimed at probing the antige-
nicity of TPO [27], but was limited to the MPO-like domain only. The vicinity to and orienta-
tion with respect to the membrane was not considered. Subsequent identification of an
autoepitope encompassing the C-terminal region of TPO prompted the modelling of the EGF-
like and CCP-like domains [28]. The study demonstrated the need to consider the structure of
the entire extracellular portion of TPO, not only the MPO-like domain, when investigating the
autoantigenicity of TPO. Our earlier study mapped epitope data onto a model of all the extra-
cellular domains of TPO [24], but did not consider interactions with the membrane.
In this work we have used a molecular modelling approach combined with molecular
dynamics (MD) simulations to investigate plausible models of TPO dimer organisation, and
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how they may be used to gain insight into the nature of its autoepitopes. This study highlights
the need to consider TPO’s oligomeric state, conformational properties, and proximity to the
membrane, in the context of its enzymatic function when interpreting antigenicity data.
Materials and Methods
Modelling
Template sequences were selected by querying the TPO protein sequence against the Protein
Databank (PDB) using the NCBI BLAST web server (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
The MPO-like, EGF-like, and CCP-like domains were modelled using for templates Protein
Data Bank (PDB) entries 1CXP [16], 1EMO [29], and 1VVD [30], respectively. Specifically, we
used the following residues for modelling: MPO-like domain (residues 142–738 modelled
using residues 167–744 from template 1CXP, 47% sequence identity), CCP-like domain
Fig 1. Schematic showing domain organization of TPO, as determined from sequence analysis. The protein sequence is coding an N-terminal
propeptide domain (yellow), a MPO-like domain (green) with a catalytic heme (red) that is connected to a CCP-like (Shamrock green), and an EGF-like (cyan-
blue) domains, an anchoring trans-membrane domain (dark-blue) and an intracellular domain (dark-magenta).
doi:10.1371/journal.pone.0142615.g001
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(residues 740–795 modelled using residues 147–202 from template 1VVD, 35% sequence iden-
tity), and EGF-like domain (residues 798–839 modelled using residues 2162–2205 from tem-
plate 1EMO, 39% sequence identity). The cholinesterase-like (ChEL) domain of thyroglobulin
was modelled using the crystal structure of recombinant human acetylcholinesterase in the apo
state (PDB ID: 4EY4) [31] as a template. Transmembrane regions of TPO were identified using
the membrane protein prediction server TMHMM [32], which found a transmembrane helix
immediately after the EGF-like domain. A putative helix-helix interaction motif was identified
as reported [33]. For the generation of the transmembrane helices dimer, the structure of a
GxxxG motif dimer (PDB ID: 2L2T)[34] was used as a template. 200 homology models of
human TPO (residues 142–880) were built using MODELLER v9.12 [35] and sorted by their
Discrete Optimized Protein Energy (DOPE) score. The inter-dimer disulfide bridge (residues
153 in 1CXP) was modelled in the TPO dimer model, as was the iron-protoporphyrin IX
(heme) group. Symmetry was maintained using MODELLER symmetry restraints between the
two chains. Model plausibility was assessed by visual inspection of domain juxtaposition, and
by determining the quality of the models using three separate assessments of model quality: (1)
VERIFY 3D [36], which determines the compatibility of an atomic model with its own amino
acid sequence by assigning a structural class based on its location and environment (alpha,
beta, loop, polar, nonpolar etc.) and comparing the results to good structures. All models pass
the VERIFY 3D test; (2) MolProbity [37], a widely used method (used by the PDB, for exam-
ple) to asses the stereochemical quality of structures; (3) QMEAN Server for model quality esti-
mation [38] (http://swissmodel.expasy.org/qmean), a method for the estimation of the
absolute quality of individual protein structure models which is independent of protein size.
Preparation of MD systems
The initial coordinates for TPO isoforms 1 and 4 were modelled as described above. Each iso-
form was then embedded in 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) membrane
and solvated in water using CHARMM-GUI [39]. DMPC lipids are widely used in studies that
employ MD because they are well parameterized and simulation outcome is in good agreement
with experimental data regarding physical properties such as area per lipid, bilayer thickness
and electron density profile [40, 41]. Water molecules were then randomly replaced with Ca2+,
necessary for TPO activity, and Na+ counter-ions, in order to neutralize any net charges in sim-
ulated systems. Simulation boxes were built such that the minimum distance between any pro-
tein atom to the box face is 20 Å. Initially, each system was subjected to 50,000 steps of energy
minimization. The simulated systems were then gradually heated to 300 K over 0.2 ns, with the
protein heavy-atoms harmonically constrained, under the canonical ensemble (NVT) condi-
tions. Following this, each system was simulated with the heavy-atoms constraints gradually
removed for 0.55 ns under isothermal—isobaric ensemble (NPT) conditions.
MD simulations
MD simulations were performed using NAMD v2.9 software [42] in conjunction with the
Amber ff14SB all-atom force field [43] and TIP3P water molecules [44]. DMPC force-field
parameters were taken from [40]. The simulation timestep was set at 2fs, and the nonbonded
cut-off length was set at 10 Å, with a pair-list cut-off set at 12 Å. All simulations were run at
constant temperature (300K) and pressure (1atm) (NPT), using a Langevin damping coeffi-
cient of 5 ps−1. For each simulated system, periodic boundary conditions were used together
with the Particle Mesh Ewald algorithm for long-range electrostatic interactions [45]. System
conformations were saved every 10 ps for analysis. Each system was subjected to free
AModel of TPO
PLOSONE | DOI:10.1371/journal.pone.0142615 December 1, 2015 4 / 16
simulation on a Blue Gene/Q cluster for a total of 30 ns. Simulations were performed in dupli-
cate—each with different initial velocities—to minimize simulation biasing.
MD analysis
Analysis was performed using GROMACS [46] and visualizations using VMD 1.9.1 [47]. Fig-
ures and movies were rendered using VMD and PyMol 1.3 [48]. Root mean square deviation
(RMSD) of backbone heavy atoms with respect to their initial structure were calculated every
10 ps, after performing a least-squares fit to their initial structure.
Results and Discussion
Modelling the structure and architecture of the extra-cellular domains of
TPO
High sequence identity between human TPO and proteins with known structures enabled homol-
ogy modelling of the three extracellular domains (S1 Fig). Crystal structures are available for LPO
andMPO, both of which have high sequence identity to the MPO-like domain of TPO [16, 17].
However, MPO is a more reasonable template as it forms disulphide-linked dimers, whereas LPO
is monomeric. TPO functions as a dimer, linked via a conserved intermolecular disulphide bond
at the same location as in MPO (TPO Cys296) at the dimer interface [8, 49] [10]. Therefore, we
modelled the MPO-like domain (residues 142–738) using the crystal structure of humanMPO.
The dimer interface in the MPO structure defines the relative orientation of the monomers in the
TPOmodel. Unlike other known peroxidases, TPO has a transmembrane (TM) domain, as well
as CCP-like and EGF-like domains linking the MPO-like domain and the TM domain (Fig 1).
The CCP-like (residues 740–795) and EGF-like (residues 796–846) domains likewise have high
sequence identity homologues for which structures are known (S1 Fig). Together, this enabled
homology modelling of all three extracellular domains and the TM domain of TPO (Fig 2).
Transmembrane helix association
A 25 amino-acid sequence has previously been identified as a likely transmembrane domain
using hydropathy profiling [11]. Bioinformatic analysis [50] of this region suggests an α-helical
conformation. Upon closer inspection of this region, we identified a transmembrane helix
dimerization motif, G860xxxG864 (S1 Fig). The GxxxG motif is indicative of a dimeric coiled-
coil structure of transmembrane helices [33, 51, 52]. There are two additional features that sup-
port transmembrane helix dimerization in TPO. First, the isoleucine that precedes the first gly-
cine in the motif is frequently seen in transmembrane helices [51]. Second, there is a threonine
in the 4th position after the GxxxG motif (S1 Fig); GxxxGxxxT is the most represented three-
residue pattern subset of the LIxxGVxxGVxxT seven-residue helix-helix dimerization motif
[51, 53]. We therefore were able to incorporate this predicted transmembrane helix dimeriza-
tion motif into the architecture of TPO with a high degree of confidence (Fig 2).
TPO domain organisation and enzyme function
Although the MPO-like domain of TPO can be modelled as a dimer using the known crystallo-
graphic disulphide-linked dimer of MPO, the spatial organisation of the MPO-like domains
relative to the CCP-like and EGF-like domains and membrane cannot be determined from pri-
mary sequence alone. There are several factors that allow for two alternative arrangements: the
order of the domains in the TPO primary sequence, symmetry restraints, the dimerization
interface inferred from the structure of MPO, and the predicted dimerization in the TM
domain (Fig 2). Modelling demonstrated that the two alternative dimeric arrangements, which
AModel of TPO
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Fig 2. A comparison betweenmembrane-embedded, dimeric models of TPO isoform1 in two different conformations. (A) Schematic of trans model
with active site facing away from follicular membrane. Coloring as in Fig 1; (B) Cis model with active site facing towards follicular membrane; (C)
perpendicular views of trans model; (D) perpendicular views of cis model. TPO represented as cartoon and space filling (subunits A and B, respectively) for
clarity. Domains are coloured as follows: MPO-like domain (green), CCP-like domain (Shamrock green), EGF-like domain (cyan-blue), and TM domain (dark-
blue). Catalytic heme represented as red spheres, and DMPCmolecules represented as lines and coloured as CPK.
doi:10.1371/journal.pone.0142615.g002
AModel of TPO
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differ in their orientation of the MPO-like domain, were both equally plausible from a purely
structural perspective. Model quality and plausibility were assessed by visual inspection of
domain juxtaposition, in combination with three separate assessments of model quality (see
methods and S1 Table).
Consideration of the enzymatic function of TPO should be taken into account in determin-
ing which of these two arrangements is the most likely architecture. TPO catalyses two vital
reactions for thyroid synthesis: iodination of tyrosine residues in thyroglobulin, and coupling
of the resulting iodotyrosines to form the thyroid hormones T3 and T4 [1]. This process is
dependent upon the heme group being covalently bound to TPO [54]. The two possible models
for TPO orient the cavity containing the heme facing either the thyroid follicular lumen (the
“trans”model; Fig 2A and 2C) or the thyrocyte membrane (the “cis”model; Fig 2B and 2D).
In the cis model, orienting the active site of TPO towards the thyrocyte membrane (Fig 2B
and 2D) would strongly prohibit access by thyroglobulin. Thyroglobulin is a 2748 residue pro-
tein, existing as a 660 kDa homodimer [55]. This is approximately three times the size of TPO.
Three of the four known iodinated tyrosines that are used to form thyroid hormones on human
thyroglobulin are located in its C-terminal portion, known as the carboxyl-terminal cholinester-
ase-like (ChEL) domain for its similarity to and proposed evolutionary origin from acetylcholin-
esterase [56]. We modelled a potential reaction in which the tyrosine residues in thyroglobulin
would require close proximity to the active site of TPO. Specifically, we modelled a 520-residue
region comprising the ChEL domain of thyroglobulin based on homology with acetylcholines-
terase. This small fragment, approximately one tenth of the thyroglobulin dimer, is only just
small enough to fit within the space underneath the active site in the cis model of TPO (S2 Fig).
Thyroglobulin is ellipsoidal, with the smaller dimension between 110 and 145 Å [55, 57, 58].
The space underneath the active site in the cis model of TPO only allows access to shapes of up
to approximately 50 Å wide (estimated by measuring the dimensions of the cavity manually).
Furthermore, thyroglobulin dimerizes via its ChEL domain [59], excluding the possibility of the
ChEL domain extending out from the rest of the protein to gain access to the active site of TPO.
However, there is as yet no conclusive kinetic evidence that iodination occurs via formation of a
TPO-bound iodinated intermediate, and the mechanism of Tg iodination may be nonspecific
[60]. Therefore, both trans and cis models are equally plausible based upon enzymatic function.
Interestingly, a fully active, naturally-occurring TPO isoform exists which does not contain
the EGF-like domain (termed isoform4; the full length molecule is known as isoform1) [61].
Molecular models of isoform4 can be built in both the trans and the cis conformations (S3 Fig).
Taken together, modelling in the context of enzyme function produces two equally plausible
forms of the TPO dimer.
TPOmodels are energetically stable
Having explored the likely dimeric arrangement of TPO, we next used MD simulations in
order to assess the structural viability of the trans and cis models of isoform1 and isoform4.
Simulations were performed after inserting the model into a DMPC lipid bilayer. Short simula-
tions indicate that both models represent viable conformations of the TPO dimer bound to the
membrane, supporting the plausibility of the dimeric trans and cis models (S4 Fig). Small
structural changes of the trans-membrane spanning helices are consistent with typical behav-
iour of proteins in MD simulations and also reflect inaccuracies inherent in a homology model.
Oligomeric architecture of TPO plays role in its autoantigenicity
Having explored the structure and dynamics of TPO dimers, we next mapped the known epi-
topes onto both the trans and cis models. Epitope mapping studies have identified two
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immunodominant regions: immunodominant region A (IDR-A) and immunodominant
region B (IDR-B) (S2 Table), initially defined with murine monoclonal antibodies [4, 20, 21].
These two IDRs were independently identified using human anti-TPO antibody Fabs, confus-
ingly also named A and B, but transposed [23, 62]. We continue to use the initial nomenclature
of Ruf et al. [4, 20, 21] who first identified the two IDR regions on TPO. Mapping these regions
onto the trans model of the TPO dimer places IDR-B on the thyrocyte membrane-facing side
of the MPO-like domain, in a closely arranged cluster near the MPO-MPO dimer interface
(Fig 3). Similarly, on the cis model IDR-B clusters closely together near the dimer interface on
the lumen facing side of the TPO molecule (Fig 4).
This finding suggests that engagement of antibody with IDR-B on both trans and cis models
of TPOmay require conformational change of TPO, and perhaps even dissociation of the dimer
into monomers. The latter possibility is consistent with the identification of both monomeric
and dimeric forms of autoantigenic TPO [8, 27, 63–65]. In addition, although the identification
of a plausible C-terminal transmembrane dimerization motif supports a dimeric arrangement,
the observation of LPOmonomers as well as the absence of monomer-monomer interactions
mediated via CCP-like or EGF-like domains in our models supports the plausibility of autoanti-
bodies binding monomeric TPO. It is important to note that dimerization does not bring
together IDRs from respective monomers in either cis or trans models (Figs 3 and 4). IDR-B,
which is located on the underside of the MPO-like domain near the MPO-MPO interface on
the trans model, shows the closest proximity of epitopes from each monomer, but they are still
too separated to participate in the same antibody-binding interaction in a single epitope.
The epitopes of IDR-A, mapped onto the trans and cis model are not as closely grouped
together as the epitopes of IDR-B (Figs 3 and 4). The features of our models (i.e. domains con-
nected by flexible linkers) are consistent with some degree of inter-domain conformational
flexibility, and as such, it is plausible that domain movements may consolidate the IDR-A epi-
tope. Specifically, the CCP-like domain may be positioned such that the 766–775 epitope
region on the CCP-like domain fits in place between the 377–386, 353–363 regions and the
713–720 regions on the MPO-like domain. This would connect all the epitope regions identi-
fied as part of IDR-A. To investigate this, we built several models (in both trans and cis) based
on templates with this postulated arrangement of domains. Our attempts indicated that via
this route, there is insufficient sequence length to cover the distance between the C-terminal
end of the MPO domain and the N-terminal end of the transmembrane domain. Further,
dimerization may prevent the CCP-like domain from positioning in between the IDR-A epi-
topes on the MPO-like domain. However, independent observations call into question the role
of the 766–775 region in the IDR-A epitope. Specifically, the Y772A mutant protein failed to
traffic to the cell surface, and, more importantly, reacted very poorly with both IDR-A and
IDR-B-specific Fabs, IDR-B-specific polyclonal rabbit antiserum to TPO-derived peptide P14,
or rabbit polyclonal antiserum to TPO [66, 67]. It has previously been shown that when both
the CCP- and EGF-like domains are deleted from TPO, there is no significant impact on TPO
reactivity with autoantibodies [68] and TPO-specific recombinant human Fabs [69]. Taken
together, these results suggest that mutations in this region may decrease the stability of the
protein, thereby indirectly weakening autoantibody binding. We have recently observed this
phenomenon in the type 1 diabetes autoantigen glutamate decarboxylase 65 (GAD65) whereby
epitope-mapping by mutagenesis affects both protein stability and conformational properties,
giving a false-positive readout for some epitope regions (Porebski et al, unpublished).
Whereas IDR-A is solvent accessible in the trans TPO dimer (Fig 3) and therefore available
to antibodies, IDR-B is somewhat occluded and may require dissociation into monomers
before becoming more accessible at antibodies. In contrast, in the cis model IDR-B epitope
regions cluster at the top of the MPO-like domain on TPO near the dimer interface, and are
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Fig 3. Mapping epitopes onto the trans TPO dimer. (A) Epitopes and residues identified in various studies as constituting immunodominant regions IDR-A
(blue) and IDR-B (pink); (B)Membrane-facing side of MPO-like domain; (C) Close-up shows that much of the two immunodominant regions are on the
membrane-facing surface of the MPO-like domain, particularly IDR-B; (D) Lumen-facing side of TPO. Hemes are shown in orange.
doi:10.1371/journal.pone.0142615.g003
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Fig 4. Mapping epitopes onto the cis TPO dimer. (A) Epitopes and residues identified in various studies as constituting immunodominant regions IDR-A
(blue) and IDR-B (pink); (B) Lumen-facing side of MPO-like domain; (C) Close-up shows that much of the two immunodominant regions are on the lumen-
facing surface of the MPO-like domain near the dimer interface, particularly IDR-B; (D)Membrane-facing side of TPO containing the heme (orange) cavity.
doi:10.1371/journal.pone.0142615.g004
AModel of TPO
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fully solvent-accessible (Fig 4). Given its likely orientation in the membrane, epitopes on the
cis model face the lumen and may be more easily accessible to autoantibodies. IDR-A is surface
exposed and scattered across the molecule, as in the trans model, but in much closer proximity.
Calculation of electrostatic potential surfaces on both the cis and trans models reveals a hetero-
geneous electrostatic distribution spread across the molecular surfaces, with no discernable
electrostatic pattern distinguishing epitope from non-epitope regions (S5 Fig). However,
inspection of the electrostatic surface of the anti-TPO TR1.9 Fab crystal structure [70] reveals
some degree of charge complementarity between the CDR regions and the 713–720 region on
the IDR-A epitope of the MPO-like domain on both the cis and trans models of TPO (S6A
Fig). The relative sizes of TPO and human IgG antibody are shown in S6B Fig to illustrate the
concept of steric occlusion of an antibody to the TPO epitopes, and how this may be affected
by the conformational properties of TPO.
Taken together, our modelling suggests that the cis dimer is slightly more favourable than
the trans dimer, based on the spatial arrangement and accessibility of epitopes. However, disso-
ciation of the dimer is likely to significantly alter the conformational properties of TPO and
thus its interaction with autoantibodies. We note that the enzyme bound to the apical mem-
brane is not accessible to the immune system; it may be that during 'reverse endocytosis' to
release the thyroid hormone products in the blood, conformational changes and/or dissocia-
tion into monomers allow antibody interaction. Alternatively, it has been proposed that auto-
antibodies may reach TPO by transcytosis across epithelia, via a membrane Fc receptor
expressed by thyrocytes [71]. Our findings invite further investigation of the relationship
between antibody binding and oligomeric state, for example using mutagenesis to favour
monomer formation, as well as probing potential interactions between the CCP- and MPO-
like domains. The timescale of our MD simulations, and the inaccuracies inherent in a homol-
ogy model, prevent further exploration of conformational change at this stage. Such an investi-
gation would require an experimentally-determined structure as a starting point for long
timescale (>100 microseconds) simulations, which are technically challenging with current
state-of-the-art computational hardware.
Conclusions
We present here refined models of a membrane-bound TPO, providing a much-needed plat-
form for structurally interpreting epitope data and highlighting new avenues for investigation
of the breakdown of immune tolerance to TPO in thyroid autoimmune disease. Both trans and
cis models of dimeric TPO are equally likely based upon conformational properties as well as
enzyme function, with the cis model being slightly more favorable based upon spatial position-
ing of epitopes. This visualization of the extensive epitope mapping data on both models of the
TPO dimer provides structural insights into the basis of TPO autoantigenicity and a platform
for further investigation. Both architectures may implicate significant conformational plasticity
upon engagement with autoantibodies, suggesting that the oligomeric state and conformational
properties of TPO play important roles in its autoantigenicity.
Supporting Information
S1 Fig. Sequence alignment of template structures to TPO sequence. Immunodominant epi-
topes are boxed and labelled. Domains and motifs are indicated by coloured bars.
(PNG)
S2 Fig. The cis model of TPO (left) and ChEL domain of thyroglobulin (right), shown on
the same scale. Two of the three tyrosines that are iodinated in ChEL are shown in blue (the
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remaining tyrosine is not in the construct that was crystallised). Heme groups in the buried
interior of the MPO-like domains are shaded. TPO domain locations are labelled.
(PNG)
S3 Fig. Model of TPO isoform4, which does not contain the EGF-like domain, in (A) trans
and (B) cis conformations. One monomer is shown as cartoon, the other as molecular surface.
MPO-like domains are coloured green, CCP-like domains are cyan. The transmembrane helix
is blue, with one heme group shown in red.
(PNG)
S4 Fig. RMSD plots for representative trajectories fromMD simulations of TPO isoform1
and 4, trans (A) and cis (B) models. Average Cα backbone RMSDs (n = 1) were found to sta-
bilize after deviating 8.5 Å for isoform1-trans, 5 Å for isoform1-cis, 4.5 Å for isoform 4-trans,
and 4 Å for isoform 4-cis. RMSDs indicate that equilibrium is reached after approximately 12
ns for the trans model and 10 ns for the cis model.
(PNG)
S5 Fig. Electrostatic surface of trans (A) and cis (B) models contoured at ±3 kT/e (blue is
+ve, red is—ve). IDR-A is shown in pink sticks, IDR-B is shown in blue sticks and heme is
shown in orange.
(PNG)
S6 Fig. (A) Electrostatic surface potential of the TR1.9 Fab CDR and its respective IDR-A epi-
tope on the trans and cis model. Electrostatic surfaces are contoured at ±3 kT/e (blue is +ve, red
is—ve). CDR loops are also shown underneath the transparent molecular surface; (B) Relative
size and scale of an IgG molecule and the trans model of TPO, with IDR-A coloured in blue and
IDR-B coloured in magenta. This reveals the restricted space available for antibody binding.
(PNG)
S1 Table. Assessment of homology model quality. 1Number of unfavorable all-atom steric
overlaps 0.4Å per 1000 atoms. 2MolProbity score combines the clashscore, rotamer, and Rama-
chandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.
100th percentile is the best among structures of comparable resolution; 0th percentile is the worst.
3Global score of the whole model reflecting the predicted model reliability ranging from 0 to 1.
4Estimate of the "degree of nativeness" of the structural features observed in a model by describing
the likelihood that a model is of comparable quality to high-resolution experimental structures.
(DOCX)
S2 Table. Epitopes and residues identified in various studies as constituting immunodomi-
nant regions A (blue, left) and B (pink, right) mapped onto the TPOmodel.
(DOCX)
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